Treatment Updates on Chronic Inflammatory Demyelinating Polyneuropathy
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC
This activity is supported by independent educational grants from Grifols, and CSL Behring.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION
Thursday, July 27, 2017 from 12:00pm – 1:00pm EDT.
The enduring material will be available from July 27, 2017 to July 27, 2018.
At the conclusion of this activity, participants will be able to:
||Conduct thorough and timely evaluation, clinical aspects, and differential diagnosis of patients with chronic inflammatory demyelinating polyneuropathy.
||Devise appropriate treatment regimen for the effective management of chronic inflammatory polyneuropathy based on guidelines and clinical evidence.
This activity is intended for US-based neurologists, immunologists, physician assistants, nurse practitioners, and nurses who manage, or have an interest in managing patients with immune-mediated neuropathies
ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.NeuroSeriesLive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter
||Reported Financial Relationship
|Roy L. Freeman, MD, MB, ChB
Harvard Medical School
Director of Neurology
Beth Israel Deaconess Medical Center
Advisory Board: Abide Therapeutics, Acetylon Pharmaceuticals Inc., Astellas Pharma US, Inc., Biogen, Daiichi Sankyo, Dong, Grace Pharmaceuticals, Grunenthal, Insys Therapeutics, Lundbeck, Nestle, Novartis, Pfizer, Inc., Vertex Pharmaceuticals
|Richard J. Barohn, MD
Chairman, Department of Neurology
Gertrude and Dewey Ziegler Professor of Neurology
University Distinguished Professor
University of Kansas Medical Center
Consultant: NuFACTOR, PNA Centers
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Plan365, Inc., Option Care
Contracted Research: KAI Research, Teva Pharmaceutical Industries, Novartis Pharmaceuticals Corp., Sanofi Genzyme, BioMarin Pharmaceutical Inc., Cytocenetics, PTC, Eli Lilly and Co.
|Kenneth C. Gorson, MD
Professor of Neurology, Department of Neurology
St. Elizabeth’s Medical Center
Tufts University School of Medicine
Consultant: Grifols, Shire, UCB, Kedrion Biopharma Inc.
Contracted Research: Grifols, Prophase, Alexacare
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Planner
||Reprted Financial Relationship
|Anne Roc, PhD
PlatformQ Health Education, LLC
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please contact the Postgraduate Institute for Medicine at www.pimed.com.
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.